Drugs / Kedrion IVIG
Kedrion IVIG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04944979 | Mar 2021 → Dec 2026 expected | immunodeficiency disease | Kedrion S.p.A. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kedrion IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04944979 ↗ |
| Known as | Kedrion Immunoglobulin 10% | “The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).” NCT04944979 ↗ |
| Known as | KIg10 | “The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).” NCT04944979 ↗ |
| Modality | Protein / enzyme biologic | “Kedrion intravenous immunoglobulin (IVIg) 10%” NCT04944979 ↗ |
| Route | Intravenous | “Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.” NCT04944979 ↗ |